SCIENTIA ADVISORS: NEWS
Release Date: 05/01/2008Scientia Advisors Management Consultant and Managing Partner, Harry Glorikian, to speak 3nd Annual Diagnostics Asia 2008 on Personalized medicine: Therapeutic areas where it is becoming an imminent reality.
Harry Glorikian, Managing Partner and Management Consultant of Scientia Advisors, will be speaking at the 2nd Annual Diagnostics Asia on Personalized medicine: Therapeutic areas where it is/becoming an imminent reality. The topics discussed will be:
Key Topics:
Harry Glorikian's experience allows him to cover a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides unique and insightful perspectives. Harry has 15 years of experience in the life sciences developing and executing key strategic acquisitions and licensing arrangements targeting revenue growth channels. Harry currently leads Scientia, including the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. His clients include both emerging innovators and global market leaders.
For more information please visit: http://www.ibc-asia.com
Click here to download PDF versionKey Topics:
- Personalized medicine overview: Definition, key trends & drivers,and adoption by key stakeholders of healthcare
- Therapeutic areas most influenced by personalized medicine: Oncology,Infectious disease and Cardiology
- Implication of migration to personalized medicine
Harry Glorikian's experience allows him to cover a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides unique and insightful perspectives. Harry has 15 years of experience in the life sciences developing and executing key strategic acquisitions and licensing arrangements targeting revenue growth channels. Harry currently leads Scientia, including the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. His clients include both emerging innovators and global market leaders.
For more information please visit: http://www.ibc-asia.com
